Stock Events

Stock Events

Regenxbio 

$8.94
53
-$0.26-2.83% Friday 20:00
+$0.02+0.22%Friday 23:44After hours

Statistics

Day High
8.96
Day Low
8.93
52W High
16.19
52W Low
5.46
Volume
39,346
Avg. Volume
-
Mkt Cap
590.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.72
-0.99
-0.27
0.46
Expected EPS
-1.208455
Actual EPS
N/A

Financials

-113.75%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
170.44MRevenue
-193.88MNet Income

Analyst Ratings

18.80Average Price Target
The highest estimate is 29.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGNX. It's not an investment recommendation.
NVIDIA
15
NVDA
Microsoft
12
MSFT
Tesla
12
TSLA
Amazon
12
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical Inc. competes in the gene therapy space, focusing on rare diseases, similar to Regenxbio's target market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has expanded into gene therapy through acquisitions and development, making it a competitor in the same therapeutic areas as Regenxbio.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has made significant investments in gene therapy, including acquiring AveXis, positioning it as a competitor in Regenxbio's market.
Abeona Therapeutics
ABEO
Mkt Cap338.53M
Abeona Therapeutics Inc. develops gene and cell therapies for serious genetic diseases, overlapping with Regenxbio's focus areas.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics, Inc. is involved in the development of gene therapies for rare diseases, particularly in neuromuscular diseases, competing with Regenxbio's gene therapy approach.

About

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Show more...
CEO
Curran Simpson
Employees
371
Country
United States
ISIN
US75901B1070
WKN
000A140E0

Listings

STU
DE
RB0.STU
XNAS
US
RGNX
MU
DE
RB0.MU
F
DE
RB0.F

0 Comments

Share your thoughts

FAQ

What is Regenxbio stock price today?▼
The current price of RGNX is $8.94 USD — it has decreased by -2.83% in the past 24 hours. Watch Regenxbio stock price performance more closely on the chart.
What is Regenxbio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Regenxbio stocks are traded under the ticker RGNX.
Is Regenxbio stock price growing?▼
RGNX stock has fallen by -7.45% compared to the previous week, the month change is a -20.74% fall, over the last year Regenxbio has showed a -7.93% decrease.
What is Regenxbio market cap?▼
Today Regenxbio has the market capitalization of 590.16M
When is the next Regenxbio earnings date?▼
Regenxbio is going to release the next earnings report on November 11, 2026.
What were Regenxbio earnings last quarter?▼
RGNX earnings for the last quarter are 0.43 USD per share, whereas the estimation was 0.08 USD resulting in a +446.19% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regenxbio revenue for the last year?▼
Regenxbio revenue for the last year amounts to 170.44M USD.
What is Regenxbio net income for the last year?▼
RGNX net income for the last year is -193.88M USD.
How many employees does Regenxbio have?▼
As of September 06, 2026, the company has 371 employees.
In which sector is Regenxbio located?▼
Regenxbio operates in the Health & Wellness sector.
When did Regenxbio complete a stock split?▼
Regenxbio has not had any recent stock splits.
Where is Regenxbio headquartered?▼
Regenxbio is headquartered in ROCKVILLE, United States.